|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/15/23 Soul Biotechnology Corp. 10-Q 3/31/23 38:2.2M Empire Filings/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 508K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 16K
3: EX-32.1 Certification -- §906 - SOA'02 HTML 14K
9: R1 Cover HTML 59K
10: R2 Consolidated Balance Sheets (Unaudited) HTML 95K
11: R3 Consolidated Balance Sheets (Unaudited) HTML 22K
(Parenthetical)
12: R4 Consolidated Statements of Operations (Unaudited) HTML 98K
13: R5 Consolidated Statements of Changes in HTML 44K
Shareholders' Deficit (Unaudited)
14: R6 Consolidated Statements of Cash Flows (Unaudited) HTML 61K
15: R7 Organization and Description of the Business HTML 32K
16: R8 Summary of Significant Accounting Assumptions and HTML 53K
Policies
17: R9 Going Concern HTML 18K
18: R10 Business Acquisition HTML 36K
19: R11 Intangible Assets HTML 17K
20: R12 Related Party Transactions HTML 21K
21: R13 Common Stock and Common Stock Payable HTML 23K
22: R14 Subsequent Events HTML 16K
23: R15 Summary of Significant Accounting Assumptions and HTML 92K
Policies (Policies)
24: R16 Business Acquisition (Tables) HTML 31K
25: R17 Organization and Description of the Business HTML 31K
(Details Narrative)
26: R18 Summary of Significant Accounting Assumptions and HTML 18K
Policies (Details Narrative)
27: R19 Going Concern (Details Narrative) HTML 18K
28: R20 Business Acquisition (Details) HTML 19K
29: R21 Business Acquisition (Details 1) HTML 35K
30: R22 Business Acquisition (Details Narrative) HTML 28K
31: R23 Intangible Assets (Details Narrative) HTML 25K
32: R24 Related Party Transactions (Details Narrative) HTML 21K
33: R25 Common Stock and Common Stock Payable (Details HTML 42K
Narrative)
36: XML IDEA XML File -- Filing Summary XML 61K
34: XML XBRL Instance -- soulbiotechno_10q_htm XML 322K
35: EXCEL IDEA Workbook of Financial Reports XLSX 58K
5: EX-101.CAL XBRL Calculations -- adob-20230331_cal XML 80K
6: EX-101.DEF XBRL Definitions -- adob-20230331_def XML 141K
7: EX-101.LAB XBRL Labels -- adob-20230331_lab XML 408K
8: EX-101.PRE XBRL Presentations -- adob-20230331_pre XML 321K
4: EX-101.SCH XBRL Schema -- adob-20230331 XSD 58K
37: JSON XBRL Instance as JSON Data -- MetaLinks 202± 285K
38: ZIP XBRL Zipped Folder -- 0001829126-23-003413-xbrl Zip 108K
Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
I, Rachel Martinuik, certify that:
1. I have reviewed this Quarterly report on Form 10-Q of Soul Biotechnology Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of a quarter report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
| Dated: May 15, 2023 | By: | /s/ Rachel Martinuik |
| Rachel Martinuik | ||
| Chief Executive Officer | ||
(Principal Executive Officer and Principal Financial Officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/15/23 | None on these Dates | ||
| For Period end: | 3/31/23 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/10/22 Soul Biotechnology Corp. 8-K:1,2,3,5 2/10/22 14:1.2M Empire Filings/FA 12/14/20 Soul Biotechnology Corp. 10-12G/A 5:709K EdgarAgents LLC/FA 11/18/20 Soul Biotechnology Corp. 10-12G/A 6:838K EdgarAgents LLC/FA 1/19/18 Soul Biotechnology Corp. S-1 6:1M S2 Filings LLC/FA |